Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb 24:372:n135.
doi: 10.1136/bmj.n135.

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials

Emily Herrett  1 , Elizabeth Williamson  2 , Kieran Brack  3 , Danielle Beaumont  3 , Alexander Perkins  2 , Andrew Thayne  3 , Haleema Shakur-Still  3 , Ian Roberts  3 , Danielle Prowse  3 , Ben Goldacre  4 , Tjeerd van Staa  5 , Thomas M MacDonald  6 , Jane Armitage  7 , Jon Wimborne  8 , Paula Melrose  8 , Jayshireen Singh  9 , Lucy Brooks  10 , Michael Moore  11 , Maurice Hoffman  12 , Liam Smeeth  1 ; StatinWISE Trial Group
Collaborators, Affiliations
Randomized Controlled Trial

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials

Emily Herrett et al. BMJ. .

Abstract

Objective: To establish the effect of statins on muscle symptoms in people who had previously reported muscle symptoms when taking statins.

Design: Series of randomised, placebo controlled n-of-1 trials.

Setting: Primary care across 50 sites in the United Kingdom, December 2016 to April 2018.

Participants: 200 participants who had recently stopped or were considering stopping treatment with statins because of muscle symptoms.

Interventions: Participants were randomised to a sequence of six double blinded treatment periods (two months each) of atorvastatin 20 mg daily or placebo.

Main outcome measures: At the end of each treatment period, participants rated their muscle symptoms on a visual analogue scale (0-10). The primary analysis compared symptom scores in the statin and placebo periods.

Results: 151 participants provided symptoms scores for at least one statin period and one placebo period and were included in the primary analysis. Overall, no difference in muscle symptom scores was found between the statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; P=0.40)). Withdrawals because of intolerable muscle symptoms were 18 participants (9%) during a statin period and 13 (7%) during a placebo period. Two thirds of those completing the trial reported restarting long term treatment with statins.

Conclusions: No overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo was found in participants who had previously reported severe muscle symptoms when taking statins. Most people completing the trial intended to restart treatment with statins. N-of-1 trials can assess drug effects at the group level and guide individual treatment.

Trial registration: ISRCTN30952488, EUDRACT 2016-000141-31, NCT02781064.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the National Institute for Health Research and London School of Hygiene and Tropical Medicine for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Recruitment and participant flow. *Seven of these 46 participants never received treatment (one withdrew consent, one had intolerable symptoms, one had clinical concerns, and four for other reasons). †152 participants were included in the secondary analysis (one participant completed the patient questionnaire in two periods but the primary outcome in only one)
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fulcher J, O’Connell R, Voysey M, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405. 10.1016/S0140-6736(14)61368-4 - DOI - PubMed
    1. Cholesterol Treatment Trialists’ Collaboration . Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-15. 10.1016/S0140-6736(18)31942-1 - DOI - PMC - PubMed
    1. Collins R, Reith C, Emberson J, et al. . Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. 10.1016/S0140-6736(16)31357-5 - DOI - PubMed
    1. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123. 10.1136/bmj.f6123 - DOI - PubMed
    1. Malhotra A. Saturated fat is not the major issue. BMJ 2013;347:f6340. 10.1136/bmj.f6340 - DOI - PubMed

Publication types

Substances

Associated data